PTGX Protagonist Therapeutics, Inc.

NASDAQ
$135.26

Protagonist Therapeutics, Inc. (PTGX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.38 per share.

Protagonist Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · After Close
Earnings Whisper
-
vs ($0.38)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $143.36

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.